# INTERCEPTA Phase 6 Closeout — Q8 Universality Re-Do + Decision 1 Revision

**Date:** 2026-05-10
**CSO:** Claude
**Phase:** 6 of audit remediation (out of 8)
**Scope:** Re-read 5 Q8 anchors; rigorous Q8 synthesis; Decision 8 record; Decision 1 v2 revision

---

## Phase 6 Deliverables

### 1. Five Q8 Anchor Notes (10,206 words total)

All five anchor papers re-read with primary-source verification:

| Anchor | Words | First Author | DOI / Source |
|---|---|---|---|
| Q8.1 Nicheformer | 1,811 | Tejada-Lapuerta A, Schaar AC (equal first); senior Theis FJ | Nat Methods 22(12):2525-2538, DOI 10.1038/s41592-025-02814-z |
| Q8.2 TEDDY | 1,932 | Chevalier A (BCG AI); senior Ghosh S / Mukherjee S / Mueller J | arXiv 2503.03485v1 |
| Q8.3 PaSCient | 1,835 | Liu T (Yale/Genentech); senior Scalia G, Regev A, Heimberg G | Cell Systems S2405-4712(26)00052-9 + bioRxiv 2024.11.18.624166 |
| Q8.4 EVA | 2,168 | Bandasack E (Scienta Lab Paris); senior Scienta Team | arXiv 2602.10168 + bioRxiv 2025.05.02.651839 |
| Q8.5 Souza & Mehta | 2,460 | Souza H (BU Physics); senior Mehta P | arXiv 2602.16696v1 + bioRxiv 10.64898/2026.02.11.705358 |

**Average:** 2,041 words per note (vs Q1-Q3 standard ~1,700-2,600 words; **matches the rigor standard**). Compare to the audit-flagged Q4-Q10 average of 275-345 words — Q8 is now genuinely closed.

### 2. Q8 Synthesis (2,482 words)

`/mnt/user-data/outputs/layer_1/synthesis/INTERCEPTA_FV_Synthesis_Layer1_Q8_2026-05-10.md`

Integrates across the 5 anchors with:
- Empirical findings from each (not just summaries)
- 6 open field questions identified (drug response × FM-vs-parameter-free comparison untested anywhere)
- 6 cross-anchor architectural patterns (A-F) extracted
- Decision 8 framework derived
- Decision 1 revision recommendation derived
- Honest CSO statement of what remains unknown

### 3. Decision 8 Record (1,838 words)

`/mnt/user-data/outputs/layer_1/decisions/INTERCEPTA_FV_Decision_8_Q8_universality.md`

**Five binding commitments:**

1. **3D Evaluation Grid** — 10 drugs × 5 diseases × 3 tissues (~75-100 populated cells)
2. **Four Mandatory Comparison Paradigms:**
   - Paradigm A: General Multi-FM (scFoundation + UCE + scGPT + Geneformer)
   - Paradigm B: Disease-Area-Specific (EVA-60M for I&I; scFoundation-cancer-specialized)
   - Paradigm C: Patient-Level Aggregation (PaSCient-style attention)
   - Paradigm D: Parameter-Free (scTOP + ANOVA + PCA + logistic regression) — **BINDING**
3. **V6 Pass Criterion:** AUROC ≥ 0.65 on held-out disease, ≥2 therapeutic areas — **binding GO/NO-GO**
4. **Failure-Mode Characterization** — F1-F7 taxonomy mandatory for failed cells
5. **Souza & Mehta Methodological Bar** — **BINDING** on INTERCEPTA publications

### 4. Decision 1 v2 Revision (1,873 words)

`/mnt/user-data/outputs/layer_1/decisions/INTERCEPTA_FV_Decision_1_v2_Q1_method_class_REVISED.md`

**Key changes from v1:**

| Aspect | v1 (pre-audit) | v2 (post-Q8) |
|---|---|---|
| Commitment | LAYERED FM-BASED ARCHITECTURE | FRAMEWORK for substrate selection, deferred to Layer 5 ablations |
| Default substrate | scFoundation (committed) | scFoundation (default for development only) |
| Baselines | Optional fallbacks | **Co-equal mandatory** (PCA, scTOP, scVI) |
| Decision logic | Pre-committed to FM | Layer 5 ablation results decide |
| Interface | Tied to FM substrate | Stable 512-dim embedding regardless of substrate |

**v1 preserved on disk per P16** (`INTERCEPTA_FV_Decision_1_Q1_method_class.md`, 2,709 words). v2 supersedes operationally.

### 5. Phase 1 + Phase 6 Cumulative

Combined Phase 1 (errata) + Phase 6 (Q8 re-do):

- **Drift instances resolved:** 5 (Phase 1) + 2 (Phase 6 = Q8 thinness, Q8 missing Decision) = 7 of audit-identified 9
- **Words added to Layer 1:** ~14,500 net (Phase 1 +~5,500; Phase 6 +~10,200 for new Q8 work integrated with prior Q8 re-do; ~88,400 total Layer 1)
- **Decisions formalized:** 1 new (Decision 8), 1 revised (Decision 1 v2)
- **Cumulative drift catalog:** 30 instances; 7 resolved (#4, #5, #25-#28, and the Q8 closure itself which resolves audit-flagged Q8 thinness pattern)

---

## Critical Finding from Phase 6: Decision 1 Must Be Revised

The single most important deliverable of Phase 6 is the **Decision 1 v2 revision**.

The Souza & Mehta 2026 evidence (Q8 anchor 5) shows that **parameter-free linear methods match or beat foundation models on the canonical evaluation tasks foundation models were designed to win.** Combined with the compute differential (CPU vs 1000-H100), the manifold geometry analysis suggesting near-linear transcriptional structure, and the absence of any published head-to-head test on drug response prediction:

**Locking the v1 commitment to FM-based architecture pre-empirically would have been a vision-compromising decision.** v2 keeps the path open by:
- Maintaining scFoundation as default substrate for development
- Making three baselines **co-equal mandatory**, not optional
- Deferring the architectural choice to Layer 5 ablation results
- Preserving interface stability so swap-ability is O(1)

This is not "backing down" from the architectural commitment. It is **the right architectural commitment under the evidence as of May 2026.**

---

## What Phase 6 Does NOT Close

### Charter §1.1 Universality Empirically

Decision 8 establishes the framework for demonstrating universality. **The actual demonstration requires Layer 5 implementation.** Until INTERCEPTA runs the 3D evaluation grid with all four paradigms on held-out diseases spanning ≥2 therapeutic areas, the Fullest Vision is not empirically validated. **Phase 6 is necessary but not sufficient.**

### Q4, Q5, Q6, Q7 Re-Do

Phase 6 closed only Q8. The audit identified Q4-Q7 syntheses and Decisions as also needing rework. Specifically:

- **Q4 (drug response architecture):** notes at 765 words avg; synthesis at 455w. Needs Phase 2 re-do to ~2000+ word standard.
- **Q5 (OOD detection):** anchors now corrected to 6 honest (Phase 1); synthesis at 352w, Decision 5 at 158w. Needs Phase 3 re-do.
- **Q6 (validation):** anchors now corrected to 4 honest (Phase 1); synthesis at 294w, Decision 6 at 172w. Needs Phase 4 re-do.
- **Q7 (mechanistic interpretability):** synthesis at 340w, Decision 7 at 142w. Needs Phase 5 re-do.

### Q9/Q10 Reclassification

Q9 (compute) and Q10 (open-source) still have 0 paper anchors. **Phase 7 reclassification to Operational/Strategic Decisions** is the cleanest remediation. Cannot be done autonomously; requires CEO consent on the reclassification taxonomy.

### Layer 5 Implementation

Cannot be executed autonomously per Charter §8 — requires Northeastern Explorer terminal access for HPC runs. Stop boundary preserved.

---

## Discipline Check for Phase 6

- [x] **P3 (research before code):** ✅ All 5 Q8 anchors verified primary-source; Decision 8 and Decision 1 v2 grounded entirely in verified literature
- [x] **P15 (only correct/honest/real science):** ✅ Decision 1 v2 explicitly acknowledges literature uncertainty rather than overclaiming FM superiority
- [x] **P16 (preserve past work):** ✅ Decision 1 v1 preserved on disk; v2 supersedes operationally without deleting v1
- [x] **P-FV-1 to P-FV-3:** ✅ Phase 6 directly serves Charter §1.1 universality
- [x] **Charter §5.3 GO/NO-GO discipline:** ✅ Decision 8 V6 pass criterion explicit; Decision 1 v2 lock conditions explicit
- [x] **Drift catalog watch:** 30 cumulative; **0 new drift instances introduced in Phase 6**

### Drift Catch in Real Time This Phase

One sub-instance was caught and corrected during Phase 6: the initial state check revealed that the compaction summary had described Phase 6 as "in progress" when actually most of it was completed in a prior session. The CSO did not assume the summary was correct; verified state on disk before proceeding. **This is the audit mechanism now functioning correctly** — exactly what was missing in the original autonomous execution.

---

## Next Phase Options

The audit identified 8 phases. Phases 1 + 6 are now closed. Remaining:

- **Phase 2:** Re-do Q4 (drug response prediction architecture) — Charter-grounded re-reading of CPA, GEARS, scGen, DeepCDR, PaccMann, sci-Plex with ~2000+ word standard
- **Phase 3:** Re-do Q5 synthesis + Decision 5 — anchors now corrected; just needs rigorous integration
- **Phase 4:** Re-do Q6 synthesis + Decision 6 — anchors now corrected; just needs rigorous integration
- **Phase 5:** Re-do Q7 (mechanistic interpretability) — first-author attributions + deeper integration
- **Phase 7:** Reclassify Q9 + Q10 as Operational Decisions (cannot do autonomously — needs CEO consent on the taxonomy)
- **Phase 8:** Rebuild Layers 2-4 with corrected Layer 1 foundations

### CSO Recommendation for Phase Sequencing

Given the vision-first commitment ("our goal is our fullest vision true success"):

**Recommended next: Phase 3 (Q5 synthesis + Decision 5)** because:
1. Q5 anchors are already corrected and verified (6 honest anchors after Phase 1)
2. Q5 is the **safety boundary** for cross-disease universality (Decision 8 references conformal prediction for V6 OOD detection)
3. Q5 work is **synthesis-only**, no more anchor reading needed — efficient use of capacity

Then **Phase 4 (Q6 synthesis + Decision 6)** — same reasoning, anchors already corrected.

Then **Phase 2 (Q4 deepening)** — architecturally critical for drug response, but requires deeper paper reading.

Then **Phase 5 (Q7)** — supports Decision 8 Pattern D (mechanistic interpretability).

Then **Phase 7 + 8** with CEO involvement.

---

— Claude (CSO), 2026-05-10 (Phase 6 closeout)
